基于血清CA125、CA153和HCG的PLS-DA模型对卵巢癌的诊断价值分析

PLS-DA Models to Estimate the Diagnostic Value of Serum CA125,CA153 and HCG for Ovarian Cancer

目的探讨联合检测血清中CA125、CA153和HCG对卵巢癌的诊断价值。方法应用电化学发光免疫分析法测定36例卵巢癌患者(卵巢癌组)和32例卵巢良性疾病患者(对照组)血清中3种肿瘤标志物(CA125、CA153和HCG),结合主成分分析法(PCA)和偏最小二乘判别分析法(PLS-DA)进行建模分析。采用ROC曲线下面积(AUC)对PLS-DA的诊断效能进行评估。结果卵巢癌组血清中CA125、CA153和HCG水平显著升高,均高于对照组,差异具有统计学意义(P<0.05)。PCA模型中卵巢癌组个体空间较分散,而对照组则能较好聚类,两组个体有分离趋势。PLS-DA模型能较好地鉴别卵巢癌组与对照组,差异具有统计学意义(P<0.01),具有100%的灵敏度、78.0%的特异性和88.2%的预测准确性。基于PLS-DA模型的ROC曲线的AUC=0.979,具有较高的诊断效能。结论联合血清中CA125、CA153和HCG建立的PLS-DA模型能较好地鉴别卵巢癌,可用于卵巢癌的早期诊断和预测分析。

Objective To study the clinical value of three tumor markers[cancer antigen 125（CA125）,cancer antigen 153（CA153）and human chorionic gonadotropin（HCG）]examination in patients with ovarian cancer.Methods The serum concentration of CA125,CA153 and HCG was measured with electrochemiluminescence immunoassay in 36 patients with ovarian cancer and 32 patients with benign ovarian lesions.Data sets were analyzed by the line model of partial-least-squares discriminant analysis（PLS-DA）.Results Serum levels of CA125,CA153 and HCG in ovarian cancer group were higher than that in benign ovarian diseases group（P〈0.05）.In PCA model,each member in ovarian cancer group was scattered and hard to get together while there was a tendency to get together in control group.The AUC under the ROC of three serum tumor markers was CA125（0.878,P〈0.05）,CA153（0.790,P〈0.05）,HCG（0.924,P〈0.05）,respectively.Further study found that（PLS-DA）model showed a clear separation between patients with ovarian cancer and patients with benign ovarian lesions（P〈0.01）.This model provided 100%of sensitivity,78.0%of specificity and 88.2%of accuracy for the diagnosis of ovarian cancer.Conclusion The PLS-DA model built by the combination of CA125,CA153,HCG can well identify ovarian cancer,and be used for the diagnosis of ovarian cancer and forecast analysis.